** Forte Biosciences' FBRX.O shares down 9.6% to $12.81 post-market as co seeks equity raise
** Dallas, Texas-based firm focused on treatment of autoimmune diseases commences offering of stock and pre-funded warrants; deal size not disclosed
** Co intends to use net proceeds for working capital and other purposes, including funding clinical and preclinical development of its product candidates and other research activities
** TD Cowen. Evercore, Guggenheim Securities and Chardan jt bookrunners
** Co has ~6.6 mln shares outstanding as of May 9, per recent 10-Q filing, giving co ~$94 mln market cap
** FBRX shares on Tues closed up 11.1% at $14.17
** YTD, stock down ~38%
** All 3 analysts covering FBRX rate stock "buy" and median PT is $59, latest LSEG data reflects
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.